APOTECA TO ENGAGE IN A UNIQUE ENTERPRISE SOLUTION
FOR IV AUTOMATION AT THE OHIO STATE UNIVERSITY
AN ENTERPRISE IV COMPOUNDING SOLUTION ADVANCING
THE SCIENCE OF IV COMPOUNDING WORKFLOW AND PATIENT SAFETY
FOR IMMEDIATE RELEASE
IV Logics is excited to announce that the APOTECA™ integrated Enterprise IV Compounding Solution will be incorporated into The Ohio State University’s James Cancer Hospital and Solove Research Institute throughout its intravenous chemotherapy operations. The Solution at Ohio State features two APOTECAchemo™ robots.
The Enterprise IV Compounding Solution promotes safety and operational enhancements throughout the IV compounding process. APOTECAchemo is a robotic device that automates compounding of hazardous injectable preparations coupled with a guided approach to manual compounding on an intelligent, integrated platform that provides uniform IV compounding workflow.
With one of the newest and most technologically complete oncology pharmacy facilities in the world, The Ohio State University’s James Cancer Hospital and Solove Research Institute will deploy the solution throughout its intravenous chemotherapy operations including multiple pharmacy locations to better serve the needs of its patients.
APOTECAchemo enters its third year of US operations with unrivaled safety, effectiveness and reliability – a testament to APOTECA’s continuous engineering improvement. Advancements such as integration with closed system transfer devices, bi-directional HL-7 interface, workload efficiency enhancement, USP compliance strategies and new types of IV compounding are major accomplishments.
Finally, Peter Camp, Managing Partner of IV Logics, adds: “We welcome Ohio State as a valued customer. We hope to work with them and our existing members to advance the science of IV automation. Our collaborative approach with many of our current customers sets us apart in the market, helping us develop solutions more quickly that deliver value to those involved in patient care.”